Nadia Coakley

Ms. Nadia Coakley

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Current Oncology
Verified
Journal Article
Open access
PEP.M. Ellis
P.M. Ellis
NCNadia Coakley
Nadia Coakley
RFR. Feld
R. Feld
SKS. Kuruvilla
S. Kuruvilla
YUY.C. Ung
Y.C. Ung
Introduction: This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients—unselected, selected, and molecularly selected—in three treatment settings: first line, second line, and maintenance. Methods: Ninety-six randomized controlled trials found using the medline and embase databases form the basis of this review. Results: In the first-line setting, data about the efficacy of egfr tyrosine kinase inhibitors (tkis) compared with platinum-based chemotherapy are inconsistent. Results from studies that selected patients based on clinical characteristics are also mixed. There is high-quality evidence that an egfr tki is preferred over a platinum doublet as initial therapy for patients with an activating mutation of the EGFR gene. The egfr tkis are associated with a higher likelihood of response, longer progression-free survival, and improved quality of life. Multiple trials of second-line therapy have compared an egfr tki with chemotherapy. Meta-analysis of those data demonstrates similar progression-free and overall survival. There is consequently no preferred sequence for second-line egfr tki or second-line chemotherapy. The egfr tkis have also been evaluated as switch-maintenance therapy. No molecular marker could identify patients in whom a survival benefit was not observed; however, the magnitude of the benefit was modest. Conclusions: Determination of EGFR mutation status is essential to making appropriate treatment decisions in patients with nsclc. Patients who are EGFR mutation–positive should be treated with an egfr tki as first-line therapy. An egfr tki is still appropriate therapy in patients who are EGFR wild-type, but the selected agent should be administered as second- or third-line therapy.

1 August 2010 in Current Oncology
Verified
Journal Article
Open access
PDF file
JYJ. Younus
J. Younus
SVS. Verma
S. Verma
JFJ. Franek
J. Franek
NCNadia Coakley
Nadia Coakley
TCthe Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care
the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care
Question: Is sunitinib malate—marketed as Sutent (Pfizer Canada, Kirkland, QC)—superior to placebo or other interventions for primary outcomes of interest in adult patients with gastrointestinal stromal tumour (GIST) who have developed resistance or who exhibit intolerance to imatinib mesylate (IM)? Background: In patients with resectable disease, surgery is the mainstay of treatment for GIST; in patients with unresectable or metastatic disease, the tyrosine kinase inhibitor IM is the therapy of choice. However, some patients have primary resistance or intolerance to IM, or they progress after optimal exposure (including an escalated dose). Here, we review the evidence for treating IM-resistant GIST with sunitinib malate. Methods: Studies of sunitinib malate were identified through MEDLINE, EMBASE, the Cochrane Library databases, and Web sites of guideline organizations. Outcomes of interest included time to progression, progression-free survival, overall survival, and toxicity. Results: One phase iii randomized controlled trial, and one abstract and presentation describing that trial, served as the evidentiary base for this clinical practice guideline. Trial data confidently show that both time to progression and progression-free survival are highly statistically significant (p < 0.0001) in favour of sunitinib malate over placebo. Overall survival was improved with sunitinib malate (hazard ratio: 0.49; 95% confidence interval: 0.29 to 0.83; p = 0.007; absolute difference in weeks not reported). The most frequent of all adverse effects (experienced in greater proportion by patients on sunitinib malate) were grades 1 and 2 leucopenia (52% vs. 5% with placebo), neutropenia (43% vs. 4%), and thrombocytopenia (36% vs. 4%). Grade 3 hematologic adverse events were also reported more frequently in the sunitinib malate group, including leucopenia (4% vs. 0%), neutropenia (8% vs. 4%), lymphopenia (9% vs. 2%), and thrombocytopenia (4% vs. 0%). Toxicity comparisons did not include p values. The incidence of grades 1–3 fatigue was greater for the sunitinib malate group (34% vs. 22% with placebo). Other grade 3 nonhematologic treatment-related adverse events that occurred more frequently on sunitinib malate included hand–foot syndrome (4% vs. 0%), diarrhea (3% vs. 0%), and hypertension (3% vs. 0%). No grade 4 adverse events were observed. Conclusions: In the target population, sunitinib malate is the recommended option for second-line therapy of metastatic GIST.

13 November 2022 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Open access
KKKardi Kennedy
Kardi Kennedy
KVKathy Vu
Kathy Vu
NCNadia Coakley
Nadia Coakley
JDJennifer Daley-Morris
Jennifer Daley-Morris
LFLeta Forbes
Leta Forbes
DLDarrilyn Lessels
Darrilyn Lessels
Background: This evidence-based practice guideline was developed to update and address new issues in the handling of hazardous drugs including being compliant with NAPRA (National Association of Pharmacy Regulatory Authorities) and USP 800 (United States Pharmacopeia) standards, the use of personal protective equipment and treatment in diverse settings including in the home setting. Methods: This guideline was developed from an adaptation and endorsement of existing guidelines and from three systematic reviews. Prior to publication, this guideline underwent a series of peer, patient, methodological and external reviews to gather feedback. All comments were addressed and the guideline was amended when required. This guideline applies to and is intended for all health care workers who may come into contact with hazardous drugs at any point in the medication circuit. Results: The recommendations represent a reasonable and practical set of procedures that the intended users of this guideline should implement to minimize the opportunity for accidental exposure. These recommendations are not limited to just the point of care, but cover the entire chain of handling of cytotoxics from the time they enter the institution until they leave in the patient or as waste. Conclusions: Decreasing the likelihood of accidental exposure to cytotoxic agents within the medication circuit is the main objective of this evidenced-based guideline. The recommendations differ slightly from previous guidelines due to new evidence.

1 January 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
YUYee C. Ung
Yee C. Ung
ABAndrea Bezjak
Andrea Bezjak
NCNadia Coakley
Nadia Coakley
WEWilliam K. Evans
William K. Evans
Lung cancer is the leading cause of cancer-related deaths in both men and women in Canada.1 x 1 Canadian Cancer Society and National Cancer Institute of Canada. Canadian Cancer Statistics 2006 [internet]. National Cancer Institute of Canada, Toronto, Canada; 2006 Available at: http://www.cancer.ca/ccs/internet/standard/0,3182,3543_14279_371283_langId-en,00.html. (Accessed September 6, 2006.) Google Scholar See all References Radiation treatment (RT) is indicated for use in approximately 60% of all patients with lung cancer and is used for a variety of intents, including curative, adjuvant, neoadjuvant, and palliative.2 x 2 Tyldesley, S, Boyd, C, Schulze, K et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001; 49: 973–985 Abstract | Full Text | Full Text PDF | PubMed | Scopus (156) | Google Scholar See all References RT is most commonly applied in stage III non-small cell lung cancer (NSCLC), where it is estimated that it might be indicated for as many as 84% of patients.2 x 2 Tyldesley, S, Boyd, C, Schulze, K et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001; 49: 973–985 Abstract | Full Text | Full Text PDF | PubMed | Scopus (156) | Google Scholar See all References

26 September 2021 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
MJMichelle Rebecca Jacobson
Michelle Rebecca Jacobson
NCNadia Coakley
Nadia Coakley
MBMarcus Q Bernardini
Marcus Q Bernardini
KBKelly-Ann Branco
Kelly-Ann Branco
LELaurie M. Elit
Laurie M. Elit
RKRaymond Kim
Raymond Kim
Objective: The purpose of this guideline is to make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2. Methods: Draft recommendations were formulated based on evidence obtained through a systematic review of RCTs, comparative retrospective studies and guideline endorsement. The draft recommendations underwent an internal review by clinical and methodology experts, and an external review by clinical practitioners. Results: The literature search yielded 1 guideline, 5 systematic reviews, and 15 studies that met the eligibility criteria. Conclusions: In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 screening for ovarian cancer is not recommended. Risk-reducing surgery is recommended to reduce the risk of ovarian cancer. In the absence of contraindications, premenopausal women undergoing RRSO should be offered hormone therapy until menopause. Systemic hormone replacement therapy, is not recommended for women who have had a personal history of breast cancer. RRSO should be considered for breast cancer risk reduction in women younger than 50 years. After a breast cancer diagnosis, RRSO for breast cancer mortality reduction can be considered within two years to women who harbour a pathogenic or likely pathogenic variant in BRCA1 if younger than the recommended age range for ovarian cancer risk reduction. RRSO before the age of 40 and specifically for breast cancer treatment in BRCA2 should be considered only if recommended by their breast cancer oncologist. Following RRSO, it is not recommended to do surveillance for peritoneal cancer.